Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

Stopped The BMN 111-104 study has terminated as further optimization of the approach to achieve bio equivalence is required. The study termination was not due to any patient safety concerns.

Conditions

• Achondroplasia

Interventions

• COMBINATION_PRODUCT: BMN 111 administration via Injector Pen
• DRUG: BMN 111 administration via vial and syringe

Sponsor

BioMarin Pharmaceutical